Main Entry Criteria. Adult patients with simple, complex, or secondarily generalized refractory seizures treated with one to three antiepileptic drugs

Comparator. Pregabalin at 150 or 600 mg/day and placebo

Number of Patients. 287

Primary Outcome Variable. Seizure counts and adverse effects

Results. Pregabalin at both doses significantly reduced seizure frequency.

Main Entry Criteria. Adult patients with partial seizures on other antiepileptic drugs

Comparator. Pregabalin at 50, 150, 300, or 600 mg/day and placebo

Number of Patients. 453

Primary Outcome Variable. Seizure counts and responder rate

Results. Pregabalin at 150, 300, and 600 mg/day significantly reduced seizure frequency and had significantly higher responder rates compared to placebo.

Main Entry Criteria. Patients with postherpetic neuralgia

Comparator. Pregabalin 150 or 300 mg/day or placebo

Number of Patients. 281

Primary Outcome Variable. Pain score, sleep interruption, Short Form-36 (SF-36), and global assessment

Results. Significantly more patients in both pregabalin groups reported improvements in pain and sleep interruption compared to placebo; SF-36 scores significantly improved in bodily pain and vitality scales; there was no difference between doses of pregabalin.

Main Entry Criteria. Patients with at least a 1- to 5-year history of diabetic peripheral neuropathy, a pain score of ≥40 mm on the SF McGill Pain Questionnaire (SF-MPQ), and an average daily pain score of ≥4 on a 0 to 10 numeric pain rating scale

Comparator. Pregabalin 300 mg/day or placebo

Number of Patients. 146

Primary Outcome Variable. Mean pain scores, SF-36 Health Survey

Results. Statistically significant improvements were observed in pain scores, mean sleep interference scores, and total SF-MPQ score.

Main Entry Criteria. Patients with at least 3 months of pain following a herpes zoster infection

Comparator. Pregabalin dose based on renal function or placebo

Number of Patients. 173

Primary Outcome Variable. Seven daily pain scores